Navigation Links
SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial
Date:7/18/2011

LONDON, July 18, 2011 /PRNewswire/ --


90% Reduction in HIV Viral Load Demonstrated Compared With Normal Disease Progression

SEEK, a privately owned biopharmaceutical company specializing in immunology, announces today that it has completed a Phase Ib/II clinical trial of its HIV-v vaccine which demonstrates a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after just a single vaccine injection.

Gregory Stoloff, CEO of SEEK, commented: "This is the first time ever that an HIV vaccine has shown such a meaningful result in a human clinical trial. The next step will be to progress this to final human trials and determine the optimum dose and dosing regime to further enhance the vaccine's efficacy."

The development of an effective vaccine against HIV has been extremely difficult because the HIV virus constantly mutates. However, SEEK's HIV-v vaccine targets only the conserved regions in the internal proteins of the HIV virus which remain constant across all HIV strains. It is the first vaccine to generate both strong T-cell and antibody responses to eliminate HIV-infected cells and thus neutralise the HIV virus.  These unique features mean that the vaccine, while initially tested in an early stage of the disease as a therapeutic, could also be effective as a prophylactic, pending confirmation in a future trial.

Commenting on the results, Marta Boffito, MD, PhD, from the St. Stephen's Aids Trust and the principal investigator in the trial, said: "These are remarkable results which demonstrate HIV-v's safety and immunogenicity and, for the first time, a clinically relevant result,  as seen in the one log reduction in viral titres. HIV has long reached pandemic status and, despite growing numbers on anti-retrovirals, we are in desperate need of both a prophylactic and the
'/>"/>

SOURCE SEEK
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Biocept, Inc. Announces New CFO
2. Neogen Corporation Announces Year-End Results Conference Call
3. Elsevier Announces 2010 Journal Impact Factor Highlights
4. Summer Street Research Announces Expansion of Research Team with the Addition of Ling Wang, CFA, Senior Biotechnology Analyst
5. Oxygen Healthcare (O2h) Announces Expanded Chemistry Collaboration With Heptares Therapeutics
6. International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility
7. Emerson Ecologics Expands Partnership With Metagenics, Announces National Distribution Agreement
8. The J.R. Simplot Company Announces Innate™ All-Native Plant Technology
9. Trudeau Institute announces a discovery in the fight against sepsis
10. EffRx Announces Issuance of US Patent Providing Further Protection to EX101, Effervescent Alendronate Weekly Dosing Form
11. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Array BioPharma Inc. (NASDAQ: ... a definitive agreement with Novartis Pharma AG to acquire ... in Phase 3 development.  This agreement is conditional on the ... (GSK) on April 22, 2014, which are expected to close ...
(Date:1/22/2015)... Shimadzu Scientific Instruments today announces the ... Offering wavelength scanning from 190 to 1,100 nm, ... in a variety of industries, including environmental, food ... enables intuitive operation, while the enhanced validation, maintenance ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces the ... office space for Shire a leading biopharmaceutical company, at Two ... | RBJ,s Robert Richards , president, and Brian ... for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting ... brand-neutral, independent consultants, Protocol Networks has recently announced its ... the years, his company has attracted several clients in ... as well as others. With the success of these ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2
... DALLAS , July ... report "Bioinformatics Market - Advanced Technologies, Global,Forecast and Winning ... bioinformatics market is,expected to reach a $8.3 billion ... from,2009-2014. While knowledge management formed the largest submarket is ...
... Dr. Woo Young Lee of the Chemical Engineering ... Wang of Chemistry, Chemical Biology and Biomedical Engineering ... significant NSF funding for their research entitled, "Evaporative ... award is a reflection of the pioneering work ...
... HOPKINTON, Mass. , July 20 Caliper Life Sciences, ... company,s second quarter 2010 financial results at 9:00 a.m. ET ... Officer and Peter McAree , Chief Financial Officer, will host the ... for the future. , , ...
Cached Biology Technology:MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014 2MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014 3MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014 4NSF funds infection-resistant orthopedic research 2Caliper Life Sciences' Second Quarter 2010 Financial Results Conference Call Notice 2
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... systems. Multimodal biometric systems utilize more than one characteristic ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... 2009) The probiotic, Bacillus polyfermenticus , can help ... treated with B. polyfermenticus during the non-inflammatory period ... less inflamed and they gained more weight than mice that ... disease in which the inner tissue of the colon, the ...
... Experimental Chemotherapy (Rega Institute) and the "Centre for Drug Design ... 2.8 million euro from the British Wellcome Trust., They will ... for the treatment of infections related to the ,dengue fever ... subtropical regions. As of yet, there is neither a vaccine ...
... nanotubes are being considered for use in everything from ... remains unknown about whether these materials cause respiratory or ... Carolina State University, The Hamner Institutes for Health Sciences, ... that inhaling these nanotubes can affect the outer lining ...
Cached Biology News:Probiotic found to be effective treatment for colitis in mice 2Probiotic found to be effective treatment for colitis in mice 3Wellcome Trust funds dengue fever research in Leuven 2Study shows how carbon nanotubes can affect lining of the lungs 2
... against TATA Binding Proteins (TBP). Ascites Antibody ... and recognizes amino acids 41-57 and may ... of TBP occurs. This antibody does ... either as a nuclear extract or as ...
... sealer ideal for low to medium throughput applications. ... wide range of plates of differing heights when ... the sealer is pre-set for optimal sealing conditions ... in conjunction with ABgenes sealing foil or film ...
... CHEMICON Re-Blot Plus Western Blot Strong Antibody ... antibodies from Western blots that have been ... other isotopes. It is not recommended for ... as it is not possible to effectively ...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
Biology Products: